Financial Performance - The company reported a net profit attributable to shareholders of the listed company and the parent company for 2024 as negative, thus not meeting the conditions for profit distribution[6]. - The board of directors approved a profit distribution plan for 2024, which includes no cash dividends, no bonus shares, and no capital reserve transfer to increase share capital[6]. - The company has not achieved profitability since its listing[4]. - The company reported a revenue of ¥127,555,134.78 for 2024, a decrease of 16.73% compared to the previous year[23]. - The net profit attributable to shareholders decreased by 523.68% to -¥54,416,282.10 in 2024[23]. - The cash flow from operating activities dropped by 80.75% to ¥13,315,815.89, primarily due to a decline in sales revenue[26]. - Basic earnings per share fell to -¥0.78, a decline of 533.33% compared to the previous year[24]. - The weighted average return on net assets decreased by 3.12 percentage points to -2.53%[25]. - Total assets at the end of 2024 were ¥2,218,110,499.82, a decrease of 3.51% from the previous year[23]. - The company’s net assets attributable to shareholders were ¥2,101,667,719.87, down by 3.97% year-on-year[23]. - The revenue excluding non-core business income decreased by 16.90% to ¥126,927,351.41[23]. - The company achieved operating revenue of ¥127,555,134.78, a decrease of 16.73% compared to the same period last year[149]. - The gross margin decreased by 13.28 percentage points to 62.41%[156]. - Revenue from domestic sales was 122,042,857.92 million, down 18.64%, with a gross margin of 62.05%[156]. - Revenue from overseas sales increased significantly, with a growth rate of 76.32%, but the gross margin decreased by 3.65 percentage points to 70.52%[156]. Operational Strategies - The company plans to repurchase shares through centralized bidding in 2024[6]. - The company is implementing cost optimization strategies aimed at improving operational efficiency and increasing profit margins by G%[13]. - The company is actively seeking investment and acquisition opportunities related to its main business to enhance existing operations and integrate upstream and downstream resources[190]. - The company is planning to invest approximately $50 million in research and development for new product lines[199]. - The company is implementing new strategies to enhance operational efficiency, targeting a 5% reduction in costs[199]. - The company aims to enhance its protein technology and application solutions, focusing on innovation to provide efficient raw materials and tools for the biopharmaceutical industry[184]. - The company intends to expand its market share by increasing its business team and enhancing its marketing network, while also optimizing its sales channels to improve customer engagement[187]. - The company is focused on enhancing its technological capabilities to stay competitive in the biotechnology industry[200]. Research and Development - The company is investing in R&D, with a budget allocation of E million for the development of next-generation products and technologies[13]. - The company's R&D expenditure as a percentage of revenue increased to 39.14%, up by 9.9 percentage points from the previous year[25]. - R&D expenditure reached 49.92 million yuan, with over 300 new products and 14 new patents granted during the reporting period[37]. - The total R&D investment for the year reached ¥49,922,930.62, an increase of 11.46% compared to the previous year[119]. - The company has developed 23 core technologies and established 7 comprehensive technology platforms, enhancing its competitive edge in various biological fields[129]. - The company has launched multiple GMP-grade RNA-related products to meet differentiated innovation needs in the downstream market[45]. - The company has developed over 10,000 recombinant proteins, antibodies, and RNA-related products, providing comprehensive solutions for antibody drugs, cell therapy, gene therapy, and RNA vaccine clients[132]. - The company has established a dedicated protein research institute to enhance its R&D capabilities[200]. Market Expansion - The company is exploring market expansion opportunities in regions B and C, targeting a potential market size of D billion[13]. - The company is actively pursuing market expansion strategies, aiming to increase its market share in the biotechnology sector[200]. - Future guidance indicates a commitment to sustainable growth, with a focus on enhancing shareholder value through strategic investments and innovation[14]. - The company has completed a strategic acquisition of a smaller competitor, which is expected to increase market share by 10%[199]. - The company is exploring partnerships with key industry players to leverage synergies and enhance product offerings[199]. Governance and Compliance - The company has established a governance framework consisting of the shareholders' meeting, board of directors, supervisory board, and senior management, ensuring clear responsibilities and coordination[193]. - There were no significant differences between the company's governance and the regulations set by the China Securities Regulatory Commission[193]. - The company has not faced any issues regarding independence or autonomous operational capabilities from its controlling shareholders[193]. - The company has not reported any changes in the implementation of differential voting rights during the reporting period[196]. - The total pre-tax remuneration for the chairman and general manager, Zhu Huaxing, was CNY 878,400[197]. - The total pre-tax remuneration for the vice general manager and core technical personnel, Wang Yingming, was CNY 551,300[197]. - The total pre-tax remuneration for the vice general manager, Zhao Yujian, was CNY 143,700[197]. - The total pre-tax remuneration for the board secretary and vice general manager, Wang Duqiang, was CNY 460,800[197]. Challenges and Risks - The company has detailed the potential risk factors it may face during operations in the report[4]. - The company faces risks related to new product development and technology iteration, which may lead to uncertainties in market competitiveness[139]. - The company maintains a high inventory level, which poses a risk of inventory impairment due to long sales cycles[145]. - The company faces intensified market competition, particularly from established foreign brands in the recombinant protein market[144]. - The macroeconomic environment and overall slowdown in the biopharmaceutical industry may impact market demand and production costs[148]. User Engagement and Market Response - User data showed an increase in active users, reaching Z million, which is a W% increase year-over-year[14]. - The management reported a significant increase in user data, with a growth rate of 25% year-over-year in active users[199]. - User engagement metrics have improved, with a 30% increase in user retention rates[199]. - The company plans to increase marketing personnel and expand customer coverage to enhance customer loyalty and promote in emerging markets[157].

Financial Performance - The company's operating revenue for Q1 2025 was ¥33,444,619.29, representing a 28.20% increase compared to ¥26,087,054.66 in the same period last year[4] - The net profit attributable to shareholders was -¥11,808,403.41, a significant decline from -¥2,630,474.68 in the previous year, indicating a worsening financial performance[4] - The basic and diluted earnings per share were both -¥0.17, reflecting a decline from -¥0.04 in the same period last year[4] - The weighted average return on equity was -0.56%, a decrease of 0.44 percentage points from -0.12% in the previous year[4] - Net loss for Q1 2025 was CNY 11,808,403.41, compared to a net loss of CNY 2,630,474.68 in Q1 2024, indicating a significant increase in losses[19] - Operating profit for Q1 2025 was reported at CNY -15,553,406.18, worsening from CNY -4,997,646.70 in Q1 2024[18] Cash Flow - The net cash flow from operating activities was -¥13,275,293.49, a decrease of 275.64% compared to ¥7,558,148.81 in the same period last year[4] - Cash flow from operating activities in Q1 2025 was CNY 30,084,732.40, down from CNY 39,202,846.49 in Q1 2024, reflecting a decrease of 23.2%[21] - Cash inflow from operating activities totaled $30,995,341.75, while cash outflow was $44,270,635.24, leading to a negative cash flow[22] - The net increase in cash and cash equivalents for the period was $40,360,538.09, a significant decrease from $529,041,189.60 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,214,208,460.08, a slight decrease of 0.18% from ¥2,218,110,499.82 at the end of the previous year[5] - Total liabilities increased to CNY 121,652,748.93 from CNY 116,442,779.95, marking a rise of 4.0%[16] - The company's equity attributable to shareholders was ¥2,092,555,711.15, down 0.43% from ¥2,101,667,719.87 at the end of the previous year[5] Research and Development - Research and development expenses totaled ¥13,318,794.20, up 21.07% from ¥11,000,774.78, accounting for 39.82% of operating revenue[5] - Research and development expenses for Q1 2025 were CNY 13,318,794.20, up 21.0% from CNY 11,000,774.78 in Q1 2024, indicating a focus on innovation[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,887[9] - There were no significant changes in the top 10 shareholders or their shareholding percentages compared to the previous period[11] - The company’s repurchase account held 360,337 shares, accounting for 0.51% of the total share capital[11] Government Support - The company received government subsidies amounting to ¥275,849.48, which are closely related to its normal business operations[6] Inventory and Receivables - Accounts receivable rose to ¥62,916,585.14 from ¥59,959,090.49, indicating an increase of about 4.9%[14] - Inventory decreased to ¥70,609,687.64 from ¥76,083,001.99, showing a reduction of about 7.1%[14] - The total current assets decreased slightly to ¥1,934,663,394.24 from ¥1,956,275,857.23, reflecting a decline of approximately 1.1%[14] - The company reported a significant increase in receivables financing, which rose to ¥5,988,871.00 from ¥2,061,250.00, marking an increase of about 190%[14] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect future financial reporting[23] - The company has not disclosed any new product developments or market expansion strategies during the reporting period[12]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-016 苏州近岸蛋白质科技股份有限公司 关于 2025 年度董事、监事、高级管理人员薪酬公告 三、薪酬标准 （一）公司董事薪酬方案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）于 2024 年 4 月 26 日召开了第二届董事会第十次会议、第二届监事会第八次会议，分别审议通过《关 于 2025 年度董事薪酬方案的议案》《关于 2025 年度高级管理人员薪酬方案的议 案》《关于 2025 年度监事薪酬方案的议案》。关联董事对《关于 2025 年度董事 薪酬方案的议案》《关于 2025 年度高级管理人员薪酬方案的议案》进行回避表 决；《关于 2025 年度监事薪酬方案的议案》全部监事进行回避表决，该议案直 接提交公司 2024 年年度股东大会审议。现将有关情况公告如下：根据《公司章 程》、《薪酬与考核委员会议事规则》等有关规定，结合公司的实际经营发展情 况，并参照行业、地区的薪酬水平和职务贡献等 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-015 苏州近岸蛋白质科技股份有限公司 关于变更部分募投项目实施地点及募投项目延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州近岸蛋白质科技股份有限公司（以下简称"公司"）于 2025 年 4 月 26 日召开第二届董事会第十次会议和第二届监事会第八次会议，审议通过了《公司 关于变更部分募投项目实施地点及募投项目延期的议案》，同意公司基于审慎性 原则，结合当前募集资金投资项目（以下简称"募投项目"）实际进展情况，在 实施主体、募集资金用途及投资总额不发生变更的情况下，将募投项目"诊断核 心原料及创新诊断试剂产业化项目"的达到预定可使用状态日期由原 2025 年 9 月 延长至 2026 年 9 月；公司根据研发中心的相关规划，为提高募集资金使用效率， 在募集资金用途及投资总额不发生变更的情况下，将募投项目"研发中心建设项 目"的实施地点由上海市金山工业区金工生物标准产业园 B 区金争路 855 弄 5 号 2 幢一层变更为上海浦东新区伽利略路 ...

苏州近岸蛋白质科技股份有限公司 2024 年度董事会审计委员会履职情况报告 根据《上市公司治理准则》《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》等相关法律法规及《苏州近岸蛋白质科技股份有限公司章 程》（以下简称"《公司章程》"）、《苏州近岸蛋白质科技股份有限公司董事 会审计委员会议事规则》（以下简称"《董事会审计委员会议事规则》"）及其 他有关规定，苏州近岸蛋白质科技股份有限公司（以下简称"公司"）董事会审 计委员会（以下简称"审计委员会"）在 2024 年度积极履行审计监督职责，在 审核公司财务信息、考察聘任审计机构、监督内控工作执行情况及审议关联交易 事项等方面均发表相关意见或建议。现将 2024 年度审计委员会履职情况报告如 下： 一、审计委员会基本情况 公司第二届董事会审计委员会成员为宋夏云先生、张宗新先生和金坚先生， 主任委员由会计专业人士宋夏云先生担任，审计委员会委员任职均符合中国证监 会、上海证券交易所的相关规定及《公司章程》《董事会审计委员会议事规则》 的规定。 二、报告期内审计委员会会议召开情况 2024 年度，审计委员会共召开 4 次会议，会议的召集、召开及审议表决 ...

苏州近岸蛋白质科技股份有限公司董事会 经核查独立董事宋夏云、张宗新、金坚及其直系亲属和主要社会关系人员的 任职经历以及独立董事签署的相关自查文件，独立董事宋夏云、张宗新、金坚不 存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形，在担任公 司独立董事期间，独立董事已严格遵守中国证监会和上海证券交易所的相关规定， 确保有足够的时间和精力勤勉尽责地履行职责，作出独立判断，不受公司主要股 东、实际控制人或其他与公司存在利害关系的单位或个人的影响。公司独立董事 宋夏云、张宗新、金坚符合《上市公司独立董事管理办法》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》中对独立董事独立性的相关要 求。 苏州近岸蛋白质科技股份有限公司董事会 2025 年 4 月 29 日 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等要求，苏州近岸蛋白质科技股份有限公司（以 下简称"公司"）董事会，就公司在任独立董事宋夏云、张宗新、金坚的独立性 情况进行评估并出具如下专项意见： 关于独立董事独立性情况的专项意见 ...

往来情况专项说明 非经营性资金占用及其他关联资金 苏州近岸蛋白质科技股份有限公司 容诚专字[2025]200Z0648 号 容诚会计师事务所(特殊普通合伙) 中国·北京 本专项说明仅供近岸蛋白年度报告披露之目的使用，不得用作任何其他目的。 附件：苏州近岸蛋白质科技股份有限公司 2024 年度非经营性资金占用及其他 关联资金往来情况汇总表。 1 关于苏州近岸蛋白质科技股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 容诚专字[2025]200Z0648 号 苏州近岸蛋白质科技股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了苏州近岸蛋白质科技股 份有限公司（以下简称近岸蛋白）2024 年 12 月 31 日的合并及母公司资产负债表， 2024 年度的合并及母公司利润表、合 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-017 苏州近岸蛋白质科技股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会计政策变更系根据财政部发布的企业会计准则、解释与通知要求 等有关文件做出调整。 本次会计政策变更不会对当期和会计政策变更之前公司财务状况、经营 成果和现金流量产生重大影响。 根据财政部发布的企业会计准则、解释与通知要求，苏州近岸蛋白质科技股 份有限公司（以下简称"公司"）于 2025 年 4 月 26 日召开第二届董事会第十次 会议、第二届监事会第八次会议，审议通过《关于会计政策变更的议案》。现将 具体内容公告如下： 一、会计政策变更概述 （一）会计政策变更原因 1、2023 年 10 月，财政部发布《企业会计准则解释第 17 号》（财会〔2023〕 21 号），规定了"关于流动负债与非流动负债的划分""关于供应商融资安排 的披露""关于售后租回交易的会计处理"的相关内容，该解释规定自 2024 年 1 月 1 日起施行。 2、20 ...

苏州近岸蛋白质科技股份有限公司 2024 年度会计师事务所的履职情况评估报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上 市公司选聘会计师事务所管理办法》和《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》等相关规范性文件的规定，以及苏州近岸蛋白质科 技股份有限公司（以下简称"公司"）《董事会审计委员会工作细则》的有关规 定，现将公司 2024 年度会计师事务所的履职情况评估报告及审计委员会履行监 督职责情况报告汇报如下： 一、会计师事务所的基本情况 1、基本信息 容诚会计师事务所（特殊普通合伙）（以下简称"容诚会计师事务所"）由原 华普天健会计师事务所（特殊普通合伙）更名而来，初始成立于 1988 年 8 月， 2013 年 12 月 10 日改制为特殊普通合伙企业，是国内最早获准从事证券服务业 务的会计师事务所之一，长期从事证券服务业务。注册地址为北京市西城区阜成 门外大街 22 号 1 幢 10 层 1001-1 至 1001-26，首席合伙人刘维。 63 名从业人员近三年（最近三个完整自然年度及当年）因执业行为受到刑 事处罚 0 次、行政处罚 3 次（同一个项 ...

募集资金存放和实际使用情况鉴证报告 苏州近岸蛋白质科技股份有限公司 容诚专字[2025]200Z0647 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金存放与实际使用情况鉴证报告 | 1-3 | | 2 | 募集资金存放与实际使用情况的专项报告 | 4-8 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 募集资金存放与实际使用情况鉴证报告 容诚专字[2025]200Z0647 号 苏州近岸蛋白质科技股份有限公司全体股东： 我们审核了后附的苏州近岸蛋白质科技股份有限公司（以下简称近岸蛋白）董 事会编制的 2024 年度《募集资金存放与实际使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 四、 工作概述 我们按照《中国注册会计师其他鉴 ...